Novartis: Ovarian cancer drug disappoints in trial

Thursday, May 27, 2010 - 14:44 in Health & Medicine

(AP) -- Swiss drug maker Novartis AG said Thursday it won't ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.

Read the whole article on Physorg

More from Physorg

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net